Hera raised $2 million in seed funding and is using the proceeds to complete its second clinical trial in patients. The company is currently raising a Series A to expand those clinical trials and to commercialize the test. Hera recently formed a scientific advisory board composed of top researchers and practitioners to provide additional expertise and outside perspective as development progresses. The plan for the Series A is explicitly to fund expanded clinical work and commercialization efforts. No operating metrics (revenue or user numbers) are disclosed in the article.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

Jan 2023